Jack Anders - 07 Jan 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: RVMD
Reported as of: 07 Jan 2026
Net transaction value: -$555,500
SEC form: 4
Accepted by SEC: 09 Jan 2026, 16:20:21 UTC
Prior SEC filing: 18 Dec 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 09 Jan 2026.

Key facts

This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2026, 16:20.

Change

Previous filing in this sequence was filed on 18 Dec 2025.
Current net transaction value: -$555,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001800668 Primary reporting owner

Anders Jack

Relationship: Chief Financial Officer
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Options Exercise

Transaction value: $424,500
Shares: +10,000
Change %: +9.3%
Price: $42.45
Shares after: 118,065
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $980,000
Shares: -10,000
Change %: -8.5%
Price: $98.00
Shares after: 108,065
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -10,000
Change %: -39%
Price: $0.000000
Shares after: 15,900
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $42.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.

Footnote F2

Includes 42,338 restricted stock units.